—

Kiniksa Pharmaceuticals Ltd (KNSA) — the peer cohort

As of 2026-10-15 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Kiniksa Pharmaceuticals Ltd ranks 7 of 11 in its cohort on the Closelooknet composite (56/100) — the cohort is led by Halozyme Therapeutics Inc at 75/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
KNSA Kiniksa Pharmaceuticals Ltd 56 94 57 19 ok 3.7%
ROVI.MC Laboratorios Farmaceuticos ROVI 61 28 76 50 warn 32.4%
LNTH Lantheus Holdings Inc 59 66 73 54 info 10.6%
BHC.TO Bausch Health Companies Inc 56 71 70 82 info 19%
GALDY GALDERMA GROUP AG 55 56 57 25 info 10.2%
FAGR.BR Fagron NV 53 46 54 59 info 10.1%
ALKS Alkermes Plc 51 51 51 23 info 28%
HALO Halozyme Therapeutics Inc 75 98 94 47 ok 0.7%
DXCM DexCom Inc 66 87 80 34 watch 9.8%
ONC BeiGene, Ltd. 64 84 63 30 ok 2.9%
MEDP Medpace Holdings Inc 64 87 74 28 ok 7.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-10-15

Quick answers

Who are Kiniksa Pharmaceuticals Ltd's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Laboratorios Farmaceuticos ROVI (ROVI.MC), Lantheus Holdings Inc (LNTH), Bausch Health Companies Inc (BHC.TO), GALDERMA GROUP AG (GALDY), Fagron NV (FAGR.BR), Alkermes Plc (ALKS), Halozyme Therapeutics Inc (HALO), DexCom Inc (DXCM) and others.

How does KNSA score against its peers?

Kiniksa Pharmaceuticals Ltd's composite reads 56/100, ranking 7 of 11 in its cohort as of 2026-10-15; the cohort's highest composite is Halozyme Therapeutics Inc at 75/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - Specialty & Generic, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.